Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis.

[1]  K. Klingel,et al.  Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. , 2008, Journal of the American College of Cardiology.

[2]  S. Neubauer,et al.  Evaluation and management of the cardiac amyloidosis. , 2007, Journal of the American College of Cardiology.

[3]  H. Goldschmidt,et al.  Non‐invasive predictors of survival in cardiac amyloidosis , 2007, European journal of heart failure.

[4]  R. Falk.  Diagnosis and Management of the Cardiac Amyloidoses , 2005, Circulation.

[5]  R. Falk,et al.  Cardiovascular magnetic resonance in cardiac amyloidosis. , 2005, Circulation.

[6]  J. Gardin,et al.  American Society of Echocardiography recommendations for use of echocardiography in clinical trials. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  Udo Sechtem,et al.  Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology , 2004, Circulation.

[8]  Richard E Thompson,et al.  Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. , 2004, Journal of the American College of Cardiology.

[9]  R. Falk,et al.  Prognostic Significance of Ultrasound Myocardial Tissue Characterization in Patients With Cardiac Amyloidosis , 2002, Circulation.

[10]  E. McVeigh,et al.  Phase‐sensitive inversion recovery for detecting myocardial infarction using gadolinium‐delayed hyperenhancement † , 2002, Magnetic resonance in medicine.

[11]  A. Tajik,et al.  Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement. , 2000, The American journal of cardiology.

[12]  E J Topol,et al.  Cause of death in clinical research: time for a reassessment? , 1999, Journal of the American College of Cardiology.

[13]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[14]  R. Falk,et al.  Right ventricular dilation in primary amyloidosis: an independent predictor of survival. , 1997, The American journal of cardiology.

[15]  A J Tajik,et al.  Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. , 1996, Journal of the American College of Cardiology.

[16]  C. Tei,et al.  New non-invasive index for combined systolic and diastolic ventricular function. , 1995, Journal of cardiology.

[17]  J. Isner,et al.  Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. , 1992, The American journal of cardiology.

[18]  J. Seward,et al.  Prognostic Significance of Doppler Measures of Diastolic Function in Cardiac Amyloidosis: A Doppler Echocardiography Study , 1991, Circulation.

[19]  J. Seward,et al.  Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. , 1985, Journal of the American College of Cardiology.

[20]  S. Cowper.  Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. , 2007, Advances in dermatology.

[21]  P. Decouflé,et al.  National sources of vital status information: extent of coverage and possible selectivity in reporting. , 1990, American journal of epidemiology.

[22]  J. Carroll,et al.  Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. , 1982, The American journal of cardiology.

[23]  D. Pennell,et al.  Journal of Cardiovascular Magnetic Resonance Open Access Cardiovascular Magnetic Resonance and Prognosis in Cardiac Amyloidosis , 2022 .